Tarsus Pharmaceuticals, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request identifies 2023 Q4, this is an annual filing; the supplied filing text does not provide a clear standalone fourth-quarter income statement or cash-flow comparison. Financial statements were audited by Ernst & Young LLP, which issued an unqualified opinion.
Business context
Tarsus is a commercial-stage biopharmaceutical company. Its first and only approved product, XDEMVY (lotilaner ophthalmic solution) 0.25%, was approved in the U.S. in July 2023 and launched in August for Demodex blepharitis. The company is also developing TP-03 for meibomian gland disease (MGD), TP-04 for rosacea, and TP-05 for potential Lyme disease prophylaxis.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Product sales, net | $14.7 million | None |
| License fees and collaboration revenue | $2.7 million | $25.8 million |
| Total revenue | $17.4 million | $25.8 million |
| Cost of sales | $1.6 million | None |
| Research and development expense | $50.3 million | $42.6 million |
| Selling, general and administrative expense | $108.7 million | $44.9 million |
| Operating loss | $143.2 million | $62.7 million |
| Net loss | $135.9 million | $62.1 million |
| Net loss per share, basic and diluted | $4.62 | $2.52 |
| Cash used in operating activities | $117.5 million | $49.0 million |
At December 31, 2023, cash and cash equivalents were $224.9 million and marketable securities were $2.5 million, for combined cash, cash equivalents and marketable securities of $227.4 million. Accounts receivable was $16.6 million; inventory was $3.1 million. Total assets were $265.5 million, total liabilities $68.5 million, and stockholders’ equity $197.0 million. Term-loan principal was $30.0 million (carrying value, net, $29.8 million).
Cash provided by investing activities was $140.6 million, largely reflecting investment maturities; financing activities provided $130.2 million, including public-offering and ATM proceeds and $10.0 million of credit-facility draws. The filing does not present a meaningful mature-product gross margin: commercial sales began during the year, and cost of sales includes royalties and amortization while some pre-approval inventory costs had been expensed as R&D.
Material changes versus FY2022
- Total revenue declined by $8.4 million as China-license revenue fell from $25.8 million to $2.5 million; FY2023 also included $14.7 million of initial XDEMVY product sales.
- Net loss increased by $73.8 million, and operating cash use increased by $68.5 million.
- SG&A rose by $63.8 million, primarily reflecting commercial-launch spending, personnel additions, and corporate infrastructure. R&D increased by $7.7 million, including higher personnel and TP-05 costs, partly offset by lower TP-03 and TP-04 external program spending.
- Cash and cash equivalents increased from $71.7 million to $224.9 million, principally supported by equity issuance, ATM sales, credit draws, and investment maturities.
- Common shares outstanding increased from 26.7 million to 34.2 million. The company raised net proceeds of about $99.3 million in its August 2023 offering and $19.2 million through its ATM in December.
Outlook, commentary, risks and unusual items
- Management stated that the $227.4 million of cash, cash equivalents and marketable securities, together with expected XDEMVY sales, was expected to fund current and planned operations for at least 12 months from the filing date. This is an estimate dependent on assumptions; the company expects continued operating losses and may need additional capital.
- The credit facility provides up to $125.0 million of remaining tranched availability, subject to conditions, revenue thresholds and lender approval. The loan bears interest at the greater of prime plus 4.45% (capped at 11.45%) or 8.45%; interest-only payments run through February 2026, followed by principal amortization unless extended under specified conditions. Substantially all assets secure the facility, with a negative pledge on intellectual property.
- No formal numerical sales or earnings guidance is provided. Management said it was pursuing broad commercial payer coverage during 2024 and broad Medicare coverage in 2025; these are objectives, not guaranteed outcomes. Market adoption, payer access, pricing, gross-to-net deductions, and the accuracy of market-size estimates remain key uncertainties.
- FY2023 XDEMVY sales were concentrated among five customers, which together represented approximately 99% of product sales (percentages are rounded); those customers also represented approximately 100% of year-end receivables. The product is dependent on third-party manufacturers and suppliers, including a single-source lotilaner supplier; the company said it was qualifying additional manufacturing capacity.
- LianBio had paid Tarsus $82.5 million under the China out-license through December 31, 2023. LianBio announced a wind-down in February 2024, making future royalties and milestone receipts uncertain. Up to $22.5 million of additional regulatory milestones and up to $100.0 million of China sales-threshold milestones were identified, plus potential royalties.
- After year-end, Tarsus reported positive topline results for TP-05’s Carpo trial and TP-04’s Galatea trial in February 2024. These were topline findings, and management planned to discuss possible regulatory paths with the FDA. TP-03’s Ersa Phase 2a MGD results were positive in December 2023; regulatory path remains undetermined.
- The company recognized a $4.0 million Elanco commercial milestone as an intangible asset and began accruing royalties on XDEMVY sales. It reported no material legal proceedings and no known cybersecurity threats that materially affected or were reasonably likely to materially affect the company as of the filing.
- Other key risks include ongoing losses and financing needs, post-approval and regulatory requirements, clinical and manufacturing execution, intellectual-property and Elanco-license dependence, reimbursement and drug-pricing changes, and potential stockholder dilution.
Important facts for investors to verify
- Subsequent XDEMVY prescription growth, net sales, payer coverage, rebate and return accruals, and customer concentration.
- Actual cash burn and runway against management’s assumptions, including whether credit-facility tranches were drawn before expiry and the effect of interest and debt covenants.
- Whether LianBio’s wind-down affects the China license, remaining milestones, royalties, or any required transfer of development and commercialization responsibilities.
- Final, complete clinical data and FDA feedback or required studies for TP-03, TP-04 and TP-05; the reported findings were topline results.
- Manufacturing capacity, supplier qualification, commercial inventory costs, and the development of product gross margin as pre-approval inventory is sold.
- Potential dilution from future financing and equity awards; 6.47 million options and unvested restricted stock units were excluded from diluted loss per share as antidilutive.